EGFR and head and neck squamous cell carcinoma: Combining anti-EGFR chimeric monoclonal antibody (mAb) cetuximab (Erbitux®, Eli Lilly) with platinum-based chemotherapy and 5-fluorouracil (EXTREME regimen) showed modest improvement in overall survival (Vermorken et al., 2008) and this regimen is recommended in the National Comprehensive Cancer Network Guidelines for treatment of HNSCC (Colevas, 2018).